-
A combination of drugs is significantly more effective than either drug alone for preventing progression of benign prostatic hyperplasia (BPH), especially in high-risk men, according to a study appearing in the Dec. 17 issue of the New England Journal of Medicine.
-
Department of Health and Human Services Secretary Tommy G. Thompson has announced an interim final regulation for the Medicare Prescription Drug Discount Card Program.
-
Regular approval for another indication of imatinib mesylate (Gleevec) by Novartis Pharmaceuticals Corp. The FDA has granted imatinib mesylate (Gleevec) regular approval
-
Alefacept (Amevive), produced by Biogen, represents a new drug class for patients with chronic plaque psoriasis. The drug was approved by the U.S. Food and Drug Administration (FDA) on Jan. 31, 2003, and became available on Feb. 3, 2003.
-
GEMINI Trial; CAMELOT Trial; INVEST Trial; The Dangers of Vitamin E; FDA Actions.
-
-
Cantor and Baum, lawyers from the Yale University School of Medicine, have written an op-ed piece in the New England Journal of Medicine focusing on the central role of pharmacists in providing emergency contraception.
-
The bivalent HPV vaccine was efficacious in prevention of incident and persistent cervical infections with HPV-16 and HPV-18, and associated cytological abnormalities and lesions. Vaccination against such infections could substantially reduce incidence of cervical cancer.
-
-
IRBs and institutions might take away two important thoughts from the NIHs recent experience: First, it doesnt take more than the appearance of a conflict to harm ones reputation. Secondly, some of the measures NIH has taken in response might guide institutions in their own conflict of interest (COI) policy-making.
